JF
RLMD icon

Jump Financial’s Relmada Therapeutics RLMD Stock Holding History

Jump Financial’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-45,249
Closed -$210K – 2191
2024
Q1 		$210K Buy
+45,249
New +$218K 0.01% 1658
2021
Q4 		– Sell
-16,900
Closed -$443K – 1660
2021
Q3 		$443K Buy
+16,900
New +$452K 0.03% 519

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jump Financial's RLMD Position: Q2 2024 in Review

Jump Financial sold out of Relmada Therapeutics (RLMD) in Q2 2024, closing a stake of 45,249 shares — an estimated $210K sold.

Jump Financial first reported a position in RLMD in Q3 2021 and held it in 2 quarters. The position peaked at $443K in Q3 2021. 79 funds tracked by Wall St. Rank hold RLMD as of Q2 2024.

  • Jump Financial reported no remaining Relmada Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Jump Financial sold 45,249 Relmada Therapeutics shares in Q2 2024, an estimated $210K.
  • Jump Financial first reported a position in Relmada Therapeutics in Q3 2021 and held it in 2 quarters.
  • Jump Financial's Relmada Therapeutics position peaked at $443K in Q3 2021.
  • 79 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2024.

Based on Jump Financial's 13F filing for Q2 2024, filed 14 Aug 2024.